Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma

Molecular Cancer Therapeutics

Volumn 11, Issue 12, 2012, Pages 2654-2663

  Keating, Joanna ^a   Tsoli, Maria ^a   Hallahan, Andrew R ^c,d   Ingram, Wendy J ^c,d   Haber, Michelle ^a   Ziegler, David S ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CASPASE 9; CISPLATIN; INHIBITOR OF APOPTOSIS PROTEIN; LBW 242; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CISPLATIN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MEDULLOBLASTOMA; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; SIGNAL TRANSDUCTION; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871390666     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0352     Document Type: Article

References (29)

1. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
2. MacDonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cogen PH, et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 2003;8:174-86. (Pubitemid 36428283)
3. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
4. Cho Y-J, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29:1424-30.
5. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011;29:1400-7.
6. Valteau-Couanet D, Fillipini B, Benhamou E, Grill J, Kalifa C, Couanet D, et al. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant 2005;36:939-45. (Pubitemid 41741555)
7. Gurney JG, Kadan-Lottick NS, Packer RJ, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. Cancer 2003;97:663-73. (Pubitemid 36125844)
8. Grill J, Sainte-Rose C, Jouvet A, Gentet J-C, Lejars O, Frappaz D, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005;6:573-80. (Pubitemid 41051935)
9. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003;22:8543-67. (Pubitemid 38028527)
10. Debatin K-M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153.
11. Cummings J, Ward TH, Ranson M, Dive C. Apoptosis pathway-targeted drugs -from the bench to the clinic. Biochim Biophys Acta 2004;1705:53.
12. Schmitt CA. Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286.
13. Thibert C, Teillet MA, Lapointe F, Mazelin L, Le Douarin NM, Mehlen P. Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. Science 2003;301:843-6. (Pubitemid 36962627)
14. McCall TD, Pedone CA, Fults DW. Apoptosis suppression by somatic cell transfer of bcl-2 promotes sonic hedgehog-dependent medulloblastoma formation in mice. Cancer Res 2007;67:5179-85. (Pubitemid 46997255)
15. Fulda S, Scaf fidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation- induced apoptosis of brain tumor cells. Cell Death Differ 1998;5:884-93.
16. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR, et al. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005;92:359-65. (Pubitemid 40343153)
17. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkCis linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994;91:12867-71.
18. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007;109:1220-7. (Pubitemid 46220671)
19. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007;67:11493-8.
20. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.Mol Cancer Ther 2007;6:1951-61. (Pubitemid 47052485)
21. Ziegler DS, Keating J, Kesari S, Fast EM, Zawel L, Ramakrishna N, et al. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neurooncol 2011;13:820-9.
22. Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M, et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008;118:3109-22.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
24. Martinet W, Schrijvers DM, De Meyer GRY, Thielemans J, Knaapen MWM, Herman AG, et al. Gene expression profiling of apoptosis-related genes in human atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:2023-9.
25. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93. (Pubitemid 350103599)
26. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo . Nat Med 2002;8:808-15.
27. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8.
28. Ziegler DS, Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol 2008;20:97-103. (Pubitemid 350190988)
29. Eschenburg G, Eggert A, Schramm A, Lode HN, Hundsdoerfer P. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis. Cancer Res 2012;72:2645-56.